What's Possible With Computational Biology Before Clinical Trials?
Date: December 5, 2023
Join Diamond Age's scientific experts and draw on their expertise from working with their clients across biotech and pharma, plus prior employers like the Broad Institute, Dana-Farber and Novartis.
As biotechnology teams grow, they may be able to accelerate their drug discovery research and development with computational biology. This round table will discuss how computational biology can help biotech companies grow through all stages of drug discovery and answer questions such as:
- Director of bioinformatics and bioinformatics: Do you need one for your department?
- On staff employees: When do you build a team vs having one person on staff?
- Domain expertise: What types of expertise can be learned on-the-job vs what must be there from the beginning?
Request An Invite
Meet Our Round Table Host
Founder & CEO, Diamond Age Data Science
Broad Institute, Dana-Farber Cancer Institute, Institute for Genomic Research
Ph.D Bioinformatics from University of Oxford
Eleanor has been working at the cutting edge of bioinformatics for over 20 years.
Before founding Diamond Age, Eleanor served as the sole bioinformatician in the Center for the Development of Therapeutics at the Broad Institute of MIT and Harvard, where she helped drive drug discovery projects in cancer, cardiovascular disease, and kidney disease, among others. She also worked at the Dana-Farber Cancer Institute, where she led mid- and late-stage development of the Multiexperiment Viewer, a powerful tool for mining large genomic datasets.
Trained as a computational biologist, Eleanor has deep expertise in transcriptional profiling as well as drug discovery and development. She earned her Ph.D. bioinformatics from Oxford University under Christopher Holmes and John Quackenbush, and also holds a Master’s degree in cellular and molecular biology from the University of Wisconsin-Madison.